Lundbeckfonden Ventures
Venture Capital, Accelerator/Incubator
Active
Copenhagen, Denmark
62
31M
35
4.43
12
0.44
17
- Stages of investment
- Areas of investment
Summary
In 2009 was created Lundbeckfonden Ventures, which is appeared as VC. The main office of represented VC is situated in the Copenhagen. The company was established in Europe in Denmark.
Besides them, we counted 3 critical employees of this fund in our database.
The typical case for the fund is to invest in rounds with 4-5 participants. Despite the Lundbeckfonden Ventures, startups are often financed by New Enterprise Associates, SR One, TPG Biotech. The meaningful sponsors for the fund in investment in the same round are Pfizer Venture Investments, Seventure Partners, OUP (Osage University Partners). In the next rounds fund is usually obtained by OUP (Osage University Partners), New Enterprise Associates, SR One.
Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund. For fund there is no match between the location of its establishment and the land of its numerous investments - United States. The fund has specific favorite in a number of founders of portfolio startups. When startup sums 4 of the founder, the probability for it to get the investment is little. Among the various public portfolio startups of the fund, we may underline DBV Technologies, SNIPR Biome, Cydan Among the most successful fund investment fields, there are Biotechnology, Therapeutics.
The higher amount of exits for fund were in 2017. The fund is constantly included in 2-6 investment rounds annually. The important activity for fund was in 2016. Despite it in 2019 the fund had an activity. Speaking about the real fund results, this VC is 16 percentage points more often commits exit comparing to other organizations. Comparing to the other companies, this Lundbeckfonden Ventures performs on 1 percentage points less the average number of lead investments. The common things for fund are deals in the range of 10 - 50 millions dollars.
Investor highlights
- Industry focus
- Geo focus
Discover reliable insights
Find relevant VC investors, identify key contacts and secure funding opportunities.
Investments analytics
Analytics
- Total investments
- 62
- Lead investments
- 12
- Exits
- 17
- Rounds per year
- 4.43
- Follow on index
- 0.44
- Investments by industry
- Biotechnology (56)
- Health Care (34)
- Therapeutics (27)
- Pharmaceutical (18)
- Medical (17) Show 16 more
- Investments by region
-
- United States (33)
- France (7)
- United Kingdom (8)
- Spain (2)
- Netherlands (2) Show 4 more
- Peak activity year
- 2016
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 12
- Avg. valuation at time of investment
- 10M
- Group Appearance index
- 0.95
- Avg. company exit year
- 8
- Avg. multiplicator
- 0.55
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
Company name | Deal date | Industry | Deal stage | Deal size | Location |
---|---|---|---|---|---|
Amplyx Pharmaceuticals | 01 Aug 2017 | Biotechnology, Medical, Pharmaceutical, Clinical Trials | Late Stage Venture | 67M | United States, California, San Diego |
Coverage Cat | 03 Aug 2022 | Financial Services, Insurance | Seed | ||
Vcare Technologies P. Ltd (Diro Labs - phonebooks) | 10 Jun 2019 | Internet, Information Technology, Mobile Apps | Seed | 0 | India, Delhi, New Delhi |
VarmX | 25 May 2023 | Manufacturing, Pharmaceutical, Therapeutics | Early Stage Venture | 41M | South Holland, Leiden, Netherlands |
Similar funds
By same location
By same geo focus
By doing lead investments
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.